evipedia.ai
← Back

Platelet-Rich Plasma for Skin Rejuvenation

Evidence Review created on 09/23/2026 using AI4L / Opus 5.5

Also known as: PRP, Autologous Platelet-Rich Plasma, Autologous Platelet Concentrate, PRP Therapy, PRP Facial, Vampire Facial

Motivation

Platelet-rich plasma (PRP), popularly called the vampire facial, is a concentrate made from a person’s own blood. A small blood sample is spun at high speed to separate the platelets, which are then returned into facial skin through fine injections or during skin needling. The platelets release natural repair signals that may prompt the skin to build new collagen, the protein that keeps skin firm and smooth.

First used to help surgical wounds and sports injuries heal, the approach moved into cosmetic practice around 2010 and became widely known after heavy celebrity coverage. Clinics now offer it for wrinkles, rough texture and acne scars, usually as a series of treatments at considerable cost per session.

This review examines what controlled studies show about its effects on aging skin, scars and pigmentation, how it compares with no treatment and with other skin procedures, which risks depend on preparation and injection technique, and how it is typically delivered, for health-focused adults considering it as part of a long-term skin health strategy.

Benefits - Risks - Protocol - Conclusion

This section lists high-level overviews of platelet-rich plasma for skin rejuvenation from expert, professional and academic sources.

Only three sources discuss platelet-rich plasma for skin in substantial depth, so fewer than five are listed.

Note on priority experts: Peter Attia discusses platelet-rich plasma only within a subscriber-only hair-loss episode, and Rhonda Patrick only within a members-only question-and-answer segment focused on orthopedic uses; both were excluded as paywalled and not skin-focused. Andrew Huberman covers it only briefly for scalp hair within a broader hair-loss episode, and Life Extension gives it a single short paragraph within a general skin protocol; neither treats facial skin in depth. No dedicated content on platelet-rich plasma for skin was found from Chris Kresser or Lifespan.io.

Grokipedia

  • Platelet-rich plasma

    A broad encyclopedia-style entry covering preparation methods, classification, clinical uses including dermatology and hair loss, adverse effects, contraindications, costs and United States regulatory status.

Examine

No Examine article on platelet-rich plasma exists; Examine.com covers supplements and dietary interventions rather than in-office procedures.

ConsumerLab

No ConsumerLab article on platelet-rich plasma exists; ConsumerLab tests supplements and consumer health products rather than in-office procedures.

Systematic Reviews

This section lists systematic reviews and meta-analyses on platelet-rich plasma for skin aging, acne scars and its most serious injection risk.

Mechanism of Action

Platelet-rich plasma is made by drawing 10–60 mL of a person’s own blood into a tube containing an anticoagulant (a clot-preventing agent) and centrifuging it, concentrating platelets about 2–9 times above blood levels.

  • Growth-factor release: when activated by injured tissue or added calcium chloride or thrombin (a clotting enzyme that triggers clot formation), platelets’ alpha granules (storage sacs inside platelets) release platelet-derived growth factor (PDGF, a signal that recruits and multiplies repair cells), transforming growth factor-beta (TGF-β, a signal that switches on collagen production), vascular endothelial growth factor (VEGF, a signal for new small vessels), epidermal growth factor (EGF, a signal for surface skin-cell renewal) and fibroblast growth factor (FGF, a signal for collagen-cell growth).
  • Fibroblast activation: in cell cultures, activated platelet-rich plasma increased the multiplication of dermal fibroblasts (collagen-producing skin cells), their type I collagen output and matrix metalloproteinase-1 (MMP-1, an enzyme that clears damaged collagen so new fibers can form) (Kim et al., 2011).
  • Competing explanation: the needle or microneedle injury used for delivery is itself a wound-healing stimulus, and a split-face trial found platelet-poor plasma (plasma left after most platelets are removed) nearly as effective (Tsai et al., 2024), so part of any effect may come from the procedure itself.
  • Kinetics: most growth factors are released within an hour and platelets keep secreting for about 7 days; as the recipient’s own blood fraction, it undergoes no liver metabolism or enzyme-based clearance.

Historical Context & Evolution

Platelet-rich plasma originated in hematology in the 1970s as a transfusion product for people with low platelet counts. It was used in open-heart surgery in the late 1980s, oral and maxillofacial surgeons added it to bone grafts from the late 1990s to speed healing, and sports medicine adopted it for tendon and joint injuries in the 2000s.

It came to be considered for skin for two reasons: its wound-healing record suggested it could speed recovery after laser resurfacing, and its growth factors are signals that decline in aging skin. Around 2010 a United States physician trademarked the “Vampire Facial” (platelet-rich plasma applied during microneedling) and the “Vampire Facelift” (combined with hyaluronic acid filler), and celebrity media coverage from 2013 drove demand well ahead of controlled data.

The first masked randomized trial against saline for facial photoaging (sun-induced skin aging) appeared only in 2018 and found that participants, but not blinded dermatologists, rated the treated side as better (Alam et al., 2018). Later appraisals found most primary studies small, uncontrolled and non-standardized (Cruciani et al., 2024), while pooled trials still reported more satisfaction than controls (Chen & Zhou, 2026). Meanwhile, evidence for scar treatment and laser recovery grew firmer. Neither the enthusiastic nor the skeptical reading is settled; the open question has shifted from whether it works at all to which preparation, delivery method and indication give a reproducible effect.

Expected Benefits

Most trials below were run by practicing dermatologists and aesthetic clinics that offer the procedure, and some by device makers; this financial interest in adoption is noted here and in the Conclusion.

High 🟩 🟩 🟩

Improved Atrophic Acne Scars When Added to Microneedling or Laser

Adding platelet-rich plasma to microneedling or to ablative fractional carbon dioxide laser (a laser that vaporizes microscopic columns of skin) improves depressed acne scars more than either device alone. A meta-analysis of 14 controlled studies (472 participants) showed consistent benefit on the Goodman and Baron scale (a validated acne-scar grading scale) (Kang & Lu, 2021). A meta-analysis of 11 randomized controlled trials (RCTs, studies assigning treatment by chance) confirmed it for laser (Aljefri et al., 2022). Trials were small and rarely blinded.

Magnitude: Odds ratio (OR, how many times likelier an outcome is in one group) 2.97 (95% confidence interval [CI, the range likely to contain the true value] 1.96–4.51) for more than 50% scar improvement versus microneedling alone; OR 2.56 (95% CI 1.37–4.78) for clinical improvement versus laser alone.

Faster Recovery After Ablative Laser Resurfacing

Applied to skin right after ablative fractional carbon dioxide laser, platelet-rich plasma shortens the crusting, redness and swelling phase. A meta-analysis of 4 studies, 3 of them RCTs, found shorter crust duration and higher satisfaction than laser alone (Chang et al., 2019). A randomized trial in 22 women also found a lower erythema index (instrument-measured redness), greater elasticity and more dermal collagen on biopsy (Shin et al., 2012). The benefit applies to people combining the two procedures.

Magnitude: Crust duration shortened by a standardized mean difference (SMD, effect size in standard-deviation units) of −1.14; satisfaction OR 3.17 versus laser alone.

Increased Scalp Hair Density ⭕️ Not Central to Skin Rejuvenation

Scalp injections of platelet-rich plasma increase hair density in androgenetic alopecia (hereditary pattern hair loss). A meta-analysis of 13 RCTs from a 14-trial review (431 participants) found more hairs per square centimeter than placebo, with high heterogeneity (variation between studies) and signs of publication bias (selective publishing of positive results) (Kieling et al., 2024). This bears on hair loss rather than skin rejuvenation, although clinics often treat face and scalp from the same blood draw.

Magnitude: Mean difference +27.55 hairs/cm² (95% CI 14.04–41.06) versus placebo; hair-shaft diameter did not change significantly.

Medium 🟩 🟩

No benefit reaches Medium: the remaining skin-aging outcomes rest on trials whose participant-rated and blinded-rater results conflict, or on small uncontrolled case series and instrument readings.

Low 🟩

Improved Facial Skin Texture and Fine Lines ⚠️ Conflicted

Injected alone, platelet-rich plasma may smooth texture and fine lines. A meta-analysis of 9 RCTs found better satisfaction and objective response than controls (Chen & Zhou, 2026); a masked saline-controlled trial found no difference on dermatologist ratings (Alam et al., 2018). Net reading: a small, mostly self-perceived improvement.

Magnitude: Risk ratio (RR, ratio of an outcome’s likelihood between groups) 1.34 for satisfaction and 1.42 for objective improvement versus controls; blinded photoaging scores identical to saline at 6 months.

Lighter Facial Hyperpigmentation

Platelet-rich plasma injections or microneedling lightened melasma (patchy facial pigmentation) in most of 7 small studies (Sarkar & Gupta, 2022). For dark under-eye circles, a randomized trial found a chemical peel clearly superior (Ellabban et al., 2019).

Magnitude: Good improvement of under-eye darkening in 4.8% after platelet-rich plasma versus 47.6% after chemical peel; melasma studies were too varied to pool.

Improved Stretch Marks

Platelet-rich plasma may soften stretch marks (striae distensae, linear bands of thinned skin). A systematic review of 6 small studies, two without any control group, found clinical improvement and, on biopsy, a thicker outer skin layer and more collagen and elastin (Sawetz et al., 2021). No study used validated scores.

Magnitude: Not quantified in available studies. The included studies reported improvement without validated scores, so no effect size can be extracted.

Speculative 🟨

Dermal Collagen Remodeling

Biopsies showed more dermal collagen after injection than after saline in a non-randomized study (Abuaf et al., 2016). Collagen density is an unvalidated marker whose link to visible aging is unproven.

Slower Future Skin Aging

No study has tested whether repeated treatments slow future skin aging. The basis is mechanistic reasoning about growth-factor stimulation of fibroblasts only.

Benefit-Modifying Factors

  • Genetic factors: no gene variants are known to predict response; inherited platelet-function disorders such as von Willebrand disease (a common clotting-protein deficiency) may lower growth-factor release from the concentrate.
  • Baseline platelet count: the final concentrate reflects circulating platelets; a count near 150,000 per microliter yields a weaker preparation than 350,000 per microliter from the same device.
  • Sex: over 90% of trial participants were women, so response in men is poorly characterized; no sex-specific difference in benefit has been reported.
  • Pre-existing conditions: diabetes, smoking and heavy sun damage impair wound healing and may blunt the repair response the treatment relies on; active acne or rosacea (chronic facial redness) may limit which delivery methods are usable.
  • Age: in one uncontrolled series, younger participants with mild to moderate wrinkles responded best (Elnehrawy et al., 2017); deep wrinkles and laxity in older skin respond less, and combination approaches are common.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Injection-Site Pain, Redness, Swelling and Bruising

Needle or microneedle delivery causes pain during treatment and redness, swelling and bruising lasting about 1–7 days, reported in nearly every trial. In a masked split-face trial with saline on the other cheek, investigators judged these reactions unrelated to the platelet concentrate, pointing to the injection itself (Alam et al., 2018). A pooled analysis found no excess adverse events versus controls (Chen & Zhou, 2026). Reactions resolve without treatment.

Magnitude: In one masked trial (27 enrolled), 18 participants reported redness, 16 swelling and 14 bruising; pooled RR for adverse events versus control 1.21 (95% CI 0.50–2.92).

Medium 🟥 🟥

No risk reaches Medium: beyond transient injection reactions, serious harms are documented only in individual case reports and a single outbreak investigation.

Low 🟥

Vascular Occlusion With Vision Loss

Injection into or near a facial artery can push the concentrate backward into the eye’s arterial supply, causing sudden permanent blindness, skin death and stroke. Case reports describe this after glabellar (between-the-eyebrows) and forehead injection (Kalyam et al., 2017; Madala et al., 2024). It is rare but irreversible.

Magnitude: Not quantified in available studies. Only individual case reports exist, so no incidence rate can be calculated.

Bloodborne Infection From Unsterile Processing

Reused equipment or mishandled blood can transmit HIV (human immunodeficiency virus) and other bloodborne viruses between clients. A United States public-health investigation linked HIV infections to microneedling platelet-rich plasma facials at an unlicensed spa (Stadelman-Behar et al., 2024). The risk depends on the facility, not the product.

Magnitude: Five linked HIV diagnoses from one unlicensed spa between 2018 and 2023; the literature reports no incidence figure for licensed medical settings.

Speculative 🟨

Stimulation of Undetected Skin Cancer

Growth factors that promote cell division could theoretically accelerate an existing, undiagnosed skin cancer at the injection site. The basis is mechanistic only; no human cases have been reported.

Reaction to Bovine Thrombin Activator

Some protocols activate platelets with bovine (cow-derived) thrombin, which in surgical use has provoked clotting-disrupting antibodies (Spero, 1993). No case after facial use is reported; the basis is isolated surgical reports.

Receiving Another Person’s Blood Through Sample Mix-Up

Mislabeled or batch-processed tubes could return another client’s blood, risking a transfusion-type reaction or infection. No facial case is reported; the basis is theoretical, raised in a dermatology-association warning whose members perform the procedure.

Risk-Modifying Factors

  • Genetic factors: von Willebrand disease and rarer inherited platelet-function disorders raise bruising and bleeding at injection and blood-draw sites; no gene variants are known to modify other adverse events.
  • Baseline blood counts: a platelet count below about 100,000 per microliter (thrombocytopenia) raises bleeding risk, and hemoglobin below 10 g/dL signals anemia that makes repeated blood draws less tolerable.
  • Sex: trial populations are over 90% women, so adverse-event rates in men are poorly characterized; no sex-specific difference in harms has been reported.
  • Pre-existing conditions: anticoagulant use, liver disease, immunosuppression, active facial infection, a history of herpes labialis (recurrent lip blisters caused by herpes simplex virus) and a tendency to keloid scarring (raised, overgrown scars) raise bruising, infection or scarring risk.
  • Age: older skin is thinner with more fragile small vessels, increasing bruising, and older adults more often take anticoagulant or antiplatelet medication.

Key Interactions & Contraindications

  • Anticoagulants (clot-preventing drugs: warfarin, apixaban, rivaroxaban, dabigatran): caution — more bruising and hematoma (blood pooling under the skin). Stopping is a prescriber decision; many clinics treat through stable therapy with an international normalized ratio (INR, a clotting-time test) below 3.0 and gentle technique.
  • Antiplatelet drugs (drugs reducing platelet clumping: aspirin, clopidogrel, prasugrel): caution — blunt platelet activation, possibly reducing growth-factor release, and increase bruising. Cardioprotective aspirin is usually continued; elective aspirin is often paused 7 days before when the prescriber agrees.
  • Over-the-counter NSAIDs (non-steroidal anti-inflammatory drugs such as ibuprofen, naproxen): monitor — reversibly inhibit platelets, blunting growth-factor release and increasing bruising. Common practice is stopping 5–7 days before and 1–2 weeks after; acetaminophen (paracetamol) is the usual alternative.
  • Systemic corticosteroids (anti-inflammatory steroid drugs: prednisone, dexamethasone): caution — suppress the inflammatory repair response the treatment relies on, reducing effect. Common practice is no oral corticosteroids for 2 weeks before treatment and no steroid injection at the site for 1 month.
  • SSRIs (selective serotonin reuptake inhibitors, antidepressants such as sertraline, fluoxetine): monitor — deplete platelet serotonin, modestly increasing bruising. No dose change is usually made; cold compresses limit bruising.
  • Supplements with antiplatelet effects (fish oil, vitamin E, ginkgo, garlic, turmeric): monitor — additive bruising. Many clinics pause them 7 days before and 3 days after treatment.
  • Supplements with additive skin effects (collagen peptides, vitamin C): monitor — may add to collagen support; no harmful interaction is known, and no timing change is needed.
  • Oral isotretinoin (a vitamin A–derived acne medication): caution when combined with microneedling or laser — possible delayed healing and atypical scarring. Clinicians historically waited 6 months after stopping; shorter intervals are now debated.
  • Other skin procedures (hyaluronic acid filler, botulinum toxin, fractional laser, topical tretinoin, a prescription vitamin A cream): monitor — combined regimens add effect and downtime. Topical tretinoin is often paused 3–5 days around microneedling to limit irritation.

Populations who should avoid Platelet-Rich Plasma:

  • Platelet count below 100,000 per microliter, or a diagnosed platelet-function disorder
  • Hemoglobin below 10 g/dL
  • Sepsis (body-wide infection response), fever or active infection, including active skin infection or active herpes labialis at the treatment site
  • Active cancer, particularly blood cancers, or skin cancer within the treatment area
  • Chronic liver disease with impaired clotting (Child-Pugh Class B or C, the two more severe grades of liver-disease scoring)
  • Anticoagulant therapy with an INR above 3.0
  • Oral corticosteroids within the past 2 weeks, or steroid injection at the site within 1 month
  • Hepatitis C or HIV infection, which impair platelet function and add staff-exposure risk
  • Pregnancy and breastfeeding, for which no safety data exist

Risk Mitigation Strategies

  • Licensed setting with closed single-use kits: prevents bloodborne infection and sample mix-ups; blood stays with the client in the treatment room, and tubes, needles and microneedle cartridges are sterile, single-use and discarded after each session.
  • Safe technique in vascular danger zones: reduces vascular occlusion and blindness; glabellar, forehead and periorbital areas receive shallow injections of about 0.05 mL into the skin, or a blunt-tipped 25–27-gauge tube (cannula), from an injector trained in facial vascular anatomy.
  • Emergency plan for vision changes: limits permanent vision loss; any visual disturbance or severe pain during injection stops treatment immediately, with same-hour transfer to an ophthalmology or stroke center, since retinal damage worsens within about 90 minutes.
  • Medication and supplement holds: reduces bruising and hematoma; NSAIDs are paused 5–7 days before and 1–2 weeks after, antiplatelet supplements 7 days before and 3 days after, with prescriber approval for aspirin or anticoagulants.
  • Cold compresses and head elevation: reduces swelling and bruising; cold is applied 10 minutes per hour for the first 24 hours, and the head is elevated during sleep for 1–2 nights.
  • Pre-treatment skin examination: addresses the theoretical risk of stimulating an undetected skin cancer; the treatment area is examined before the first session and suspicious lesions are biopsied first.
  • Calcium chloride or no activator: avoids the antibody risk of bovine thrombin; most facial protocols use non-activated plasma or calcium chloride activation.

Therapeutic Protocol

  • Standard series: three sessions 4 weeks apart, then maintenance every 6–12 months; 10–60 mL of blood yields 3–8 mL of concentrate, injected into the skin at about 0.05–0.1 mL per point across the treatment zone.
  • Preparation: facial protocols typically use leukocyte-poor (low white-cell) plasma at roughly 3–6 times baseline platelet concentration; activation with calcium chloride is optional.
  • Injection into the skin alone: injected without other treatments for texture and fine lines, the approach tested by academic dermatologists at Northwestern University (Alam et al., 2018).
  • Microneedling delivery (“Vampire Facial”): popularized by Alabama physician Charles Runels; the concentrate is spread on skin during 0.5–1.5 mm microneedling, mostly for texture and acne scars.
  • Combination with filler (“Vampire Facelift”): Runels’ variant pairing the concentrate with hyaluronic acid filler; the immediate visible change comes from the filler.
  • Laser adjunct: applied or injected right after fractional carbon dioxide laser, a practice of laser dermatologists aimed at faster recovery and scar improvement (Chang et al., 2019).
  • Platelet-rich fibrin (PRF) alternative: an anticoagulant-free, low-speed-centrifuged concentrate popularized by Joseph Choukroun and Richard Miron, both of whom teach commercial training courses on it.
  • Time of day: no time-of-day data exist; afternoon appointments let swelling settle overnight, and good hydration in the preceding 24 hours eases the blood draw.
  • Half-life: not a drug; growth factors are mostly released within an hour, platelets secrete for about 7 days, and collagen remodeling continues over 3–6 months.
  • Single versus split dosing: each session is a single procedure; dosing is split across the three-session series rather than within a day.
  • Genetic factors: no pharmacogenetic variants guide dosing; inherited platelet disorders such as von Willebrand disease warrant hematology input before a series.
  • Sex: women average slightly higher platelet counts than men; no sex-specific dosing exists, and over 90% of trial participants were women.
  • Age: most trials enrolled adults aged about 30–65; older skin with deep wrinkles often receives combination approaches, such as laser or filler, rather than monotherapy.
  • Baseline biomarkers: platelet count sets final concentration; some clinics draw more blood when the count is at the low end of normal.
  • Pre-existing conditions: glucose control and smoking cessation before a series support the wound-healing response; people with diabetes or heavy sun damage may need more sessions.

Discontinuation & Cycling

  • Short-term course: used as a finite series plus optional maintenance, not as continuous lifelong therapy.
  • No withdrawal effects: stopping causes no rebound; any improvement fades gradually as normal aging continues, typically over 6–18 months.
  • No tapering: no tapering protocol applies because no drug level is maintained in the body.
  • Cycling: maintenance sessions every 6–12 months are the usual pattern; no evidence shows that pauses preserve or restore responsiveness.

Sourcing and Quality

  • Not a supplement: the concentrate is prepared on-site from the person’s own blood, so third-party product testing does not apply; quality depends on the device and the operator.
  • Cleared closed systems: Food and Drug Administration (FDA) 510(k)-cleared kits (cleared as similar to existing devices), such as Harvest SmartPReP, Arthrex Angel, EmCyte PurePRP, Regen Lab RegenKit and Eclipse PRP, provide sterile, closed processing.
  • Stated platelet concentration: reputable practitioners can state the system’s typical fold-increase over baseline and its white-cell content; some kits produce only 2–3 times baseline.
  • Provider credentials: a licensed, physician-supervised setting with documented infection control and retained client records.
  • Topical “PRP” products: cosmetic serums sold as platelet or growth-factor products are not platelet-rich plasma made from the person’s own blood and are not supported by these trials.

Practical Considerations

  • Time to effect: texture changes appear 4–12 weeks after the first session; full results are judged after the third session, roughly 3–4 months from the start.
  • Common pitfalls: expecting filler-like volume, using unlicensed spas, taking NSAIDs around sessions, stopping after one session, and unprotected sun exposure that offsets gains.
  • Regulatory status (United States): centrifuge kits are FDA-cleared for preparing platelet-rich plasma, mainly for bone-graft handling; facial injection is off-label physician practice, and reinjecting a person’s own blood within the same procedure is exempt from drug or biologic approval.
  • Cost and accessibility: about US$500–1,500 per session, usually three sessions; insurers and national health systems do not cover cosmetic use, so payers have no financial stake favoring it over cheaper options such as topical retinoids (vitamin A–derived creams).

Interaction with Foundational Habits

  • Sleep: none direct — the treatment does not affect sleep. Sleep loss impairs skin barrier recovery and collagen repair, indirectly blunting response; sleeping face-up with the head elevated for 1–2 nights limits post-treatment swelling.
  • Nutrition: indirect, potentiating — collagen synthesis requires vitamin C and adequate protein (about 1.2 g/kg daily). Hydration eases the blood draw; high-dose fish oil, garlic and turmeric may add to bruising, and alcohol is commonly avoided 24–48 hours before and after.
  • Exercise: indirect — strenuous exercise, sauna and heat within 24–48 hours after treatment raise facial blood flow and swelling. Regular aerobic exercise supports skin microcirculation; no data show exercise blunting the treatment’s effect.
  • Stress management: indirect — chronically high cortisol (the main stress hormone) impairs collagen production and wound healing. No study has tested stress effects on response; stress-related sleep loss and smoking are the practical levers.

Monitoring Protocol & Defining Success

Baseline testing before a first session typically includes a complete blood count (CBC, a panel measuring blood cells) to confirm adequate platelets and hemoglobin, ferritin (iron stores), a review of medications and supplements affecting platelets, a skin examination of the treatment area, and standardized photographs under fixed lighting. People on warfarin add a same-week INR, and people with diabetes add HbA1c (average blood sugar over about 3 months).

Ongoing monitoring follows a fixed cadence: standardized photographs and self-ratings at each session, at 1 month after the third session, then every 6 months during maintenance. A CBC is repeated annually for people on maintenance draws, or sooner if bruising, fatigue or medication changes suggest a platelet or anemia problem.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Platelet count 200–350 ×10³/µL Sets concentrate strength Conventional range 150–400 ×10³/µL; below 100 ×10³/µL treatment is avoided; no fasting needed
Hemoglobin Women 13.5–15.0 g/dL; men 14.5–16.5 g/dL Screens for anemia Conventional lower limits about 12.0 (women) and 13.5 g/dL (men); pair with ferritin
Ferritin 50–150 ng/mL Iron reserve for repeated draws Conventional range starts near 15 ng/mL; morning fasting sample preferred; inflammation raises it
Concentrate platelet level 3–6 times own blood level Confirms delivered dose Requested from the clinic or device data; not routinely measured in each session
INR (warfarin users only) 2.0–3.0 per prescriber target Bleeding risk Same-week test; not needed for other anticoagulants
HbA1c Below 5.4% Healing capacity Conventional normal below 5.7%; no fasting needed
Standardized facial photographs No established target; track change from own baseline Objective outcome Same camera, distance and lighting; skin-imaging systems optional

Qualitative markers of success:

  • Skin smoothness to the touch and under side lighting
  • Visibility of fine lines in natural light
  • Evenness of pigmentation and under-eye darkness
  • Depth of acne scars in side lighting
  • Duration of bruising and swelling after each session
  • Self-rated satisfaction on a simple 5-point scale

Emerging Research

  • Laser plus concentrate for acne scars: a recruiting randomized trial of 70 participants in Pakistan comparing fractional carbon dioxide laser with and without platelet-rich plasma, primary endpoint change in quantitative Goodman and Baron scar score (NCT07352215).
  • Cheaper alternative test: a recruiting randomized trial of 116 participants with atrophic acne scars comparing microneedling with platelet-rich plasma versus microneedling with topical insulin (NCT06978361); a match would weaken the case for the blood draw.
  • Head-to-head with laser: a randomized real-world comparison of fractional carbon dioxide laser versus platelet-rich plasma with microneedling in 116 participants in Bangladesh, graded by Goodman and Baron score; not yet recruiting (NCT07189923).
  • Fibrin versus plasma for photoaging: a double-blind randomized trial of 30 participants in Taiwan comparing PRF with platelet-rich plasma during microneedling, primary outcome Global Aesthetic Improvement Scale; status unknown (NCT06452667).
  • Are platelets necessary: a double-blind split-face trial found platelet-poor plasma nearly as effective (Tsai et al., 2024); larger trials with saline and plasma arms could weaken the case for platelet concentration.
  • Light-preconditioned concentrate: a 28-person split-face randomized trial found light-and-heat-preconditioned plasma reduced periorbital wrinkle depth more than standard preparation, with effects beyond 6 months (Wanitphakdeedecha et al., 2026), a possible way to strengthen results.
  • White-cell content: cell and mouse work suggests leukocyte-rich preparations stimulate collagen synthesis in aged fibroblasts (Oh et al., 2026), challenging the usual preference for leukocyte-poor plasma; human comparisons are lacking.
  • Standardization gap: an overview rated confidence low or critically low in 12 of 13 systematic reviews (Cruciani et al., 2024); standardized platelet dosing and blinded outcomes could confirm or overturn current findings.

Conclusion

Platelet-rich plasma is a concentrate of a person’s own platelets, returned into facial skin by injection, skin needling or after laser treatment. Its appeal is using the body’s own repair signals rather than a foreign substance.

The evidence is firmest where it serves as an add-on: it improves depressed acne scars beyond needling or laser alone and shortens recovery after laser resurfacing, and scalp injections increase hair density. For its most marketed use, smoothing wrinkles and refreshing aging skin on its own, results are mixed. Pooled trials show people are more satisfied with treated skin, yet specialists who did not know which side was treated saw no difference from saline injection in the most rigorous comparison, and plasma without concentrated platelets has performed almost as well. Gains in pigmentation, stretch marks and collagen rest on small or indirect studies.

Common side effects are brief pain, redness, swelling and bruising. Rare but serious harms, such as blindness from injection into a blood vessel and virus transmission at an unlicensed spa, depend on who performs the procedure and how.

The evidence base is small, inconsistent in preparation methods, and produced largely by dermatologists, aesthetic clinics and device makers who earn revenue from the procedure; the dermatology association cited here has members who perform it. For health-focused adults weighing cost against effect, the clearest value lies in pairing it with scar or laser treatments, with less certain returns as a stand-alone skin refresher.

Top - Benefits - Risks - Protocol